| Heather Mertz, MD | |
|
1 Medical Center Dr, Morgantown, WV 26506-1200 | |
| (855) 988-2273 | |
| Not Available |
| Full Name | Heather Mertz |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology - Maternal & Fetal Medicine |
| Location | 1 Medical Center Dr, Morgantown, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477533115 | NPI | - | NPPES |
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.
Scientists at the University of Southampton have created a new method to generate bone cells which could lead to revolutionary bone repair therapies for people with bone fractures or those who need hip replacement surgery due to osteoporosis and osteoarthritis.
The labeling information that comes with prescription drugs tells you what's known about the medication, but researchers from the Stanford University School of Medicine think it's high time that the labeling tell you what isn't known.
Verdia Inc., a wholly owned subsidiary of Maxygen, Inc. has announced today the publication in the journal Science of a study that describes the successful development of a novel glyphosate-resistant crop trait by scientists at Verdia and Pioneer Hi-Bred International, Inc., a wholly owned subsidiary of DuPont.
› Verified 8 days ago
| Entity Name | Carolinas Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774333 PECOS PAC ID: 4789597477 Enrollment ID: O20031110000116 |
News Archive
Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.
Scientists at the University of Southampton have created a new method to generate bone cells which could lead to revolutionary bone repair therapies for people with bone fractures or those who need hip replacement surgery due to osteoporosis and osteoarthritis.
The labeling information that comes with prescription drugs tells you what's known about the medication, but researchers from the Stanford University School of Medicine think it's high time that the labeling tell you what isn't known.
Verdia Inc., a wholly owned subsidiary of Maxygen, Inc. has announced today the publication in the journal Science of a study that describes the successful development of a novel glyphosate-resistant crop trait by scientists at Verdia and Pioneer Hi-Bred International, Inc., a wholly owned subsidiary of DuPont.
› Verified 8 days ago
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477878890 PECOS PAC ID: 3375449655 Enrollment ID: O20031219000455 |
News Archive
Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.
Scientists at the University of Southampton have created a new method to generate bone cells which could lead to revolutionary bone repair therapies for people with bone fractures or those who need hip replacement surgery due to osteoporosis and osteoarthritis.
The labeling information that comes with prescription drugs tells you what's known about the medication, but researchers from the Stanford University School of Medicine think it's high time that the labeling tell you what isn't known.
Verdia Inc., a wholly owned subsidiary of Maxygen, Inc. has announced today the publication in the journal Science of a study that describes the successful development of a novel glyphosate-resistant crop trait by scientists at Verdia and Pioneer Hi-Bred International, Inc., a wholly owned subsidiary of DuPont.
› Verified 8 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.
Scientists at the University of Southampton have created a new method to generate bone cells which could lead to revolutionary bone repair therapies for people with bone fractures or those who need hip replacement surgery due to osteoporosis and osteoarthritis.
The labeling information that comes with prescription drugs tells you what's known about the medication, but researchers from the Stanford University School of Medicine think it's high time that the labeling tell you what isn't known.
Verdia Inc., a wholly owned subsidiary of Maxygen, Inc. has announced today the publication in the journal Science of a study that describes the successful development of a novel glyphosate-resistant crop trait by scientists at Verdia and Pioneer Hi-Bred International, Inc., a wholly owned subsidiary of DuPont.
› Verified 8 days ago
| Entity Name | Mertz Mfm Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912577628 PECOS PAC ID: 9234520206 Enrollment ID: O20211230000139 |
News Archive
Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.
Scientists at the University of Southampton have created a new method to generate bone cells which could lead to revolutionary bone repair therapies for people with bone fractures or those who need hip replacement surgery due to osteoporosis and osteoarthritis.
The labeling information that comes with prescription drugs tells you what's known about the medication, but researchers from the Stanford University School of Medicine think it's high time that the labeling tell you what isn't known.
Verdia Inc., a wholly owned subsidiary of Maxygen, Inc. has announced today the publication in the journal Science of a study that describes the successful development of a novel glyphosate-resistant crop trait by scientists at Verdia and Pioneer Hi-Bred International, Inc., a wholly owned subsidiary of DuPont.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heather Mertz, MD 1 Medical Center Dr, Morgantown, WV 26506-1200 Ph: (855) 988-2273 | Heather Mertz, MD 1 Medical Center Dr, Morgantown, WV 26506-1200 Ph: (855) 988-2273 |
News Archive
Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.
Scientists at the University of Southampton have created a new method to generate bone cells which could lead to revolutionary bone repair therapies for people with bone fractures or those who need hip replacement surgery due to osteoporosis and osteoarthritis.
The labeling information that comes with prescription drugs tells you what's known about the medication, but researchers from the Stanford University School of Medicine think it's high time that the labeling tell you what isn't known.
Verdia Inc., a wholly owned subsidiary of Maxygen, Inc. has announced today the publication in the journal Science of a study that describes the successful development of a novel glyphosate-resistant crop trait by scientists at Verdia and Pioneer Hi-Bred International, Inc., a wholly owned subsidiary of DuPont.
› Verified 8 days ago
Erica Arthurs, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2000 Mon Health Medical Park Dr Ste 2100, Morgantown, WV 26505 Phone: 304-599-6811 Fax: 304-599-7159 | |
Allison Alexander, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1195 Pineview Dr Ste 2, Morgantown, WV 26505 Phone: 304-285-5505 Fax: 304-285-5504 | |
Dr. Kristy Kay Ward, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 304-598-4500 Fax: 304-598-4560 | |
Dr. Vicki V Baker, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1 Stadium Drive, Morgantown, WV 26506 Phone: 304-598-4800 Fax: 304-293-6963 | |
Murshid Khader Abdel-latif, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2000 Mon Health Medical Park Dr Ste 2100, Morgantown, WV 26505 Phone: 304-599-6811 Fax: 304-599-7159 | |
William K Hamilton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1200 J D Anderson Dr, Morgantown, WV 26505 Phone: 304-599-6811 | |
Dr. Amanda Gail Sherman, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2000 Mon Health Medical Park Dr Ste 2100, Morgantown, WV 26505 Phone: 304-599-6811 Fax: 304-599-7159 |